Industrial development of novel prototype antibody for Autoimmunity
| Reference number | |
| Coordinator | Genagon Therapeutics - GENAGON THERAPEUTICS AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | May 2017 - December 2017 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovativa startups fas 1 Våren 2017 |
Important results from the project
Genagon Therapeutics have developed an antibody directed against a receptor with previously unknown function. In this study the ability of the antibody to reduce the disease severity EAE was measured. The purpose was to validate the novel pharmacological target and the in vivo properties of the lead antibody. In the study different pharmaceutical compounds used in clinical practice today was compared as monotreatment or in combinatorial arms with the Genagon antibody.
Expected long term effects
The study demonstrated that the antibody reduced the disease severity more then the positive control used. The effect was further potentiated in an additive mode in combinatorial arms. The positive control is in clinical use for MS treatment. Surprisingly, the mono treatment arm with antibody alone was sufficient to reduce disease severity more then the positive control used during part of the study.
Approach and implementation
In the study a murine version of MS was studied; EAE. The animals was divided in different groups after debut of disease symptoms and the various treatments was given either as monotreatments or combinatorial arms. The disease severity in the different groups was compared over time.